1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Diabetic Peripheral Neuropathy - Pipeline Review, H1 2016

Diabetic Peripheral Neuropathy - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 58 pages

Diabetic Peripheral Neuropathy - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Diabetic Peripheral Neuropathy - Pipeline Review, H1 2016’, provides an overview of the Diabetic Peripheral Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy
- The report reviews pipeline therapeutics for Diabetic Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Peripheral Neuropathy therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Peripheral Neuropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Diabetic Peripheral Neuropathy - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Diabetic Peripheral Neuropathy Overview 7
Therapeutics Development 8
Pipeline Products for Diabetic Peripheral Neuropathy - Overview 8
Pipeline Products for Diabetic Peripheral Neuropathy - Comparative Analysis 9
Diabetic Peripheral Neuropathy - Therapeutics under Development by Companies 10
Diabetic Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 11
Diabetic Peripheral Neuropathy - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Diabetic Peripheral Neuropathy - Products under Development by Companies 14
Diabetic Peripheral Neuropathy - Products under Investigation by Universities/Institutes 15
Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development 16
Celgene Corporation 16
Commence Bio, Inc. 17
Nuvo Research Inc. 18
Pfizer Inc. 19
Relief Therapeutics S.A. 20
ViroMed Co., Ltd. 21
Diabetic Peripheral Neuropathy - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
atexakin alfa - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
benfotiamine - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
BNV-222 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
CBX-129801 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
CMB-200 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Drug for Pain - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Flexicaine - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
ketoprofen - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
PDA-002 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
PF-05089771 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
VM-202 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Diabetic Peripheral Neuropathy - Recent Pipeline Updates 48
Diabetic Peripheral Neuropathy - Dormant Projects 52
Diabetic Peripheral Neuropathy - Discontinued Products 53
Diabetic Peripheral Neuropathy - Product Development Milestones 54
Featured News and Press Releases 54
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 54
Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables
Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2016 8
Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Diabetic Peripheral Neuropathy - Pipeline by Celgene Corporation, H1 2016 16
Diabetic Peripheral Neuropathy - Pipeline by Commence Bio, Inc., H1 2016 17
Diabetic Peripheral Neuropathy - Pipeline by Nuvo Research Inc., H1 2016 18
Diabetic Peripheral Neuropathy - Pipeline by Pfizer Inc., H1 2016 19
Diabetic Peripheral Neuropathy - Pipeline by Relief Therapeutics S.A., H1 2016 20
Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co., Ltd., H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Stage and Target, H1 2016 24
Number of Products by Stage and Mechanism of Action, H1 2016 26
Number of Products by Stage and Route of Administration, H1 2016 28
Number of Products by Stage and Molecule Type, H1 2016 30
Diabetic Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H1 2016 48
Diabetic Peripheral Neuropathy - Dormant Projects, H1 2016 52
Diabetic Peripheral Neuropathy - Discontinued Products, H1 2016 53

List of Figures
Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2016 8
Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Targets, H1 2016 23
Number of Products by Stage and Targets, H1 2016 23
Number of Products by Mechanism of Actions, H1 2016 25
Number of Products by Stage and Mechanism of Actions, H1 2016 25
Number of Products by Routes of Administration, H1 2016 27
Number of Products by Stage and Routes of Administration, H1 2016 27
Number of Products by Molecule Types, H1 2016 29
Number of Products by Stage and Molecule Types, H1 2016 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Dystrophin (DMD) - Pipeline Review, H2 2016

Dystrophin (DMD) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Dystrophin (DMD) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Dystrophin (DMD) - Pipeline Review, H2 2016’, provides in depth analysis on Dystrophin (DMD) targeted pipeline therapeutics. ...

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016’, provides in ...

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2016

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.